Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilixadencel + sorafenib
- Development stage
- Unknown
- Lead developer
- Mendus
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Intratumoral, Oral
01
Overview
Ilixadencel + sorafenib is a combination therapy investigated for the treatment of advanced hepatocellular carcinoma (HCC). Ilixadencel (formerly INT-001) is an off-the-shelf, cell-based immune primer consisting of activated allogeneic dendritic cells derived from healthy donors. When injected intratumorally, it is designed to recruit and activate the patient's own immune cells, leading to a systemic, tumor-specific T-cell response. Sorafenib (Nexavar) is an orally administered small molecule multi-kinase inhibitor that targets several tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR-1, -2, -3, PDGFR-beta, and Raf kinases. While a Phase I/II trial (NCT01974661) demonstrated the safety and tolerability of the combination, clinical outcomes were limited, and preclinical data suggested that sorafenib's immunosuppressive potential might interfere with the immune-priming mechanism of ilixadencel.
- Brand names
- Nexavar
- Other names
- ilixadencel plus sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on ilixadencel + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilixadencel + sorafenib.